Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
His health and her announced on Wednesday that offers a common semaglutid in Canada as Novo nordiskPatent on their branded drugs Ozempic and Wegovy should end in January.
“Canada is the main opportunity to show what an affordable and quality care can look like,” said Andrew Dudum, co-founder and CEO of Hims & Hers, in a press release. “As the overall semaglutid first becomes available worldwide, we focus on making it really affordable, combining accessibility with trusted, personalized departure.”
The Hims, the Telehealth Platform, joins the growing list of drug manufacturers seeking to earn on a fixed patent Novo Nordisk on their GLP-1. This is the first time the company will work in Canada.
Generalics, it is essentially a copy of the brand drug, such as Ozempic or Wegovy, which provide equal efficiency, adhere to the same safety standards and are allowed when valid. These drugs differ from complex versions of drugs, which are personalized therapies that change in form or are provided at different dosage levels than available doses.
The Canadian Semaglutid Market in 2024 brought a profit of $ 1.18 billion and is expected Grand View Research.
There is still no general version of Semaglutide on the market, which was approved by the Canadian Health Agency, but the approval process has begun for some in the field.
Sandoz, World Leader in Production of Genetic Medicine, said science In early June, he applied for approval of the general version of Semaglutide with the regulatory agency Canada Canada’s health. In his message, the Hims did not say that he started a similar application for the review, but noted that he was working with an “approved partner” to make sure that he complies with all local laws and rules.
Some in this area expressed concern about the Novo let go of your patent and it happens the way the veg Lost soil by Eli Lily“A rival appeal, Zepbound, in the US, but the company’s press -secretary said CNBC that all intellectual property decisions are” carefully considered “, adding that” periods of exclusivity for pharmaceutical products end within their normal life cycle and general procedures may be accessed over time. “
This HIMS message follows from closing recent companies acquisition of European Platform Telehealth MiraclesExpanding health care platform in Europe to Ireland, France and Germany.
This also happens after Novo Nordisk ended its cooperation From him and her, citing the concern of the sales of the company and the promotion of cheaper drugs for weight loss Wegovy.
As Novo lost its Canadian patent
According to the documents submitted in Canadian Patent DatabaseNovo held a patent on Semaglutide, but the last time the company paid the annual maintenance fee in 2018.
Novo Nordisk attorneys demanded that you return the money for 2017, $ 250 ($ 185) because the company wanted more time to find out if it wants to pay it according to the letters that are included in the documents.
Two years later, the office sent a letter stating that the fee, which had a late charge, which brought a total amount of up to $ 450, did not receive the appointed period.
Novo Nordisk had an annual grace for payment but never made, and so its patent ended in Canada. It ended in 2020 when the fee was not received but will end until January.
The Canadian authorities confirmed that “after the patent is over, it cannot be revived.”
“Make affordable obesity treatment can help strengthen the local health care system and unlock the potential of millions of Canadians to live a healthier, more fulfilling life,” said David Meinert, CEO of International Business in Hims & Hers.
